Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers (2005-2009)
Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers (2005-2009)
复制标题
DOI：
10.1016/j.diagmicrobio.2010.10.020
复制
发表时间：
2011-02-01
影响因子：
2.9
通讯作者：
Jones, Ronald N.
中科院分区：
文献类型：
--
作者：
Sader, Helio S.;Farrell, David J.;Jones, Ronald N.
我们评价了替加环素对肠杆菌科（9563株）和不动杆菌属的活性。(835)2005-2009年从31个美国医学中心收集了各种耐药表型。通过参考肉汤微量稀释法检测分离株对替加环素和各种对照药物的敏感性。在大肠杆菌和克雷伯氏菌属中，产超广谱β-内酰胺酶（ESBL）的菌株分别占6.8%和15.4%;菌株对头孢他啶耐药。替加环素对E.大肠埃希菌[最低抑菌浓度（MIC 50/90），0.12/0.25 μ g/mL; 100.0%敏感]，与ESBL表型或对其他抗菌药物的耐药性无关。在克雷伯氏菌属中，产ESBL的克雷伯菌占97.9%。亚胺培南非敏感菌株对替加环素敏感率为98.2%（MIC 50/90，两个亚群均为0.5/1 μ g/mL）。替加环素对肠杆菌属有活性。（MIC 50/90，0.25/1 μ g/mL; 98.4%敏感），包括头孢他啶耐药菌株（MIC 50/90，0.5/2 μ g/mL; 97.1%敏感）。替加环素对不动杆菌的抑制率为94.4%。总体（MIC 50/90，0.5/2 μ g/mL）和86.2%的亚胺培南非敏感（MIC 50/90，1/4 μ g/mL）菌株，
We evaluated the activity of tigecycline against Enterobacteriaceae (9563 isolates) and Acinetobacter spp. (835) with various resistance phenotypes collected from 31 US medical centers in 2005-2009. The isolates were tested for susceptibility by the reference broth microdilution method against tigecycline and various comparators. Among Escherichia coli and Klebsiella spp., 6.8% and 15.4% exhibited an extended-spectrum beta-lactamase (ESBL) phenotype, respectively; and 22.2% of Enterobacter spp. strains were ceftazidime-resistant. Tigecycline was active against E. coli [minimum inhibitory concentration (MIC50/90), 0.12/0.25 mu g/mL; 100.0% susceptible] independent of ESBL phenotype or resistance to other antimicrobials. Among Klebsiella spp., 97.9% of ESBL-producing Klebsiella spp. and 98.2% of imipenem-non-susceptible strains were susceptible to tigecycline (MIC50/90, 0.5/1 mu g/mL for both subsets). Tigecycline was active against Enterobacter spp. (MIC50/90, 0.25/1 mu g/mL; 98.4% susceptible), including ceftazidime-resistant strains (MIC50/90, 0.5/2 mu g/mL; 97.1% susceptible). Tigecycline inhibited 94.4% of Acinetobacter spp. overall (MIC50/90, 0.5/2 mu g/mL) and 86.2% of imipenem non-susceptible (MIC50/90, 1/4 mu g/mL) strains at